Login to Your Account



Evotec, Harvard, J&J Combine in Preclinical Diabetes Alliance

By Cormac Sheridan
Staff Writer

Wednesday, July 11, 2012
CureBeta, the diabetes research alliance between Evotec AG and Doug Melton's lab in Harvard University's Department of Stem Cell and Regenerative Biology, has found an early taker for its preclinical portfolio of small molecules and biologics that can trigger growth of insulin-secreting pancreatic beta cells.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription